Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PSY004
MIFTS: 66

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Psychotic Disorder

About this section

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 15
Psychotic Disorders 42 15 70
Mental or Behavioural Disorder 12 17
Mental Disorders 70
Psychotic 54

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


Sources

Summaries for Psychotic Disorder

About this section
MedlinePlus : 42 Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to drug psychosis and delusional disorder, and has symptoms including photophobia, lethargy and restlessness. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Acetaminophen and Inositol have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and eye, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Wikipedia : 73 Psychosis is a condition of the mind that results in difficulties determining what is real and what is... more...

Sources

Related Diseases for Psychotic Disorder

About this section

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 679)
# Related Disease Score Top Affiliating Genes
1 drug psychosis 32.5 SLC18A2 DRD2 COMT
2 delusional disorder 32.3 PRODH HTR2A DRD4 DRD3 DRD2 DISC1
3 schizophrenia 18 32.3 SLC1A1 PRODH NRXN1
4 schizoaffective disorder 32.2 SLC6A4 SLC1A1 RGS4 PRODH PRL NRXN1
5 schizophrenia 32.2 SYN2 SLC6A4 SLC1A1 SLC18A2 RGS4 PRODH
6 schizophreniform disorder 32.2 PRODH PRL NRXN1 NRG1 HTR2A DTNBP1
7 schizophrenia 9 32.2 PRODH DISC1
8 schizophrenia 4 31.9 SLC1A1 PRODH
9 phenylketonuria 31.8 PRODH MAOB DRD2
10 tardive dyskinesia 31.3 HTR2A DRD4 DRD3 DRD2 COMT
11 melancholia 31.3 SLC6A4 PRL HTR2A BDNF
12 personality disorder 31.2 SLC6A4 PRL MAOB HTR2A DRD4 DRD3
13 alcohol use disorder 31.2 SLC6A4 PRODH HTR2A DRD3 DRD2 COMT
14 traumatic brain injury 31.2 DRD2 COMT BDNF
15 post-traumatic stress disorder 31.2 SLC6A4 NRG1 MAOB HTR2A DRD2 COMT
16 disease of mental health 31.1 SYN2 SLC6A4 SLC1A1 SLC18A2 RGS4 PRODH
17 eating disorder 31.1 SLC6A4 HTR2A DRD3 DRD2 COMT BDNF
18 bipolar disorder 31.1 SYN2 SLC6A4 SLC1A1 SLC18A2 RGS4 PRODH
19 mood disorder 31.1 SLC6A4 SLC18A2 PRODH MAOB HTR2A DRD4
20 generalized anxiety disorder 31.1 SLC6A4 HTR2A DRD2 COMT BDNF
21 panic disorder 31.0 SLC6A4 PRL HTR2A DRD4 DRD3 DRD2
22 alzheimer disease 31.0 SLC6A4 NRG1 MAOB HTR2A DRD3 DRD2
23 brain injury 31.0 DRD2 COMT BDNF
24 postpartum depression 31.0 SLC6A4 PRL COMT BDNF
25 substance abuse 31.0 SLC6A4 PRODH PRL HTR2A DRD4 DRD3
26 substance-induced psychosis 31.0 SLC6A4 SLC18A2 HTR2A DTNBP1 DRD2 COMT
27 alcohol dependence 30.9 SLC6A4 SLC18A2 MAOB HTR2A DRD4 DRD3
28 anorexia nervosa 30.9 SLC6A4 PRL HTR2A DRD4 COMT BDNF
29 social phobia 30.9 SLC6A4 PRODH PRL HTR2A DRD2 COMT
30 paranoid schizophrenia 30.9 SLC6A4 PRL NRXN1 HTR2A DISC1 COMT
31 early-onset schizophrenia 30.9 DRD2 BDNF
32 obsessive-compulsive disorder 30.9 SLC6A4 SLC1A1 PRL MAOB HTR2A DRD4
33 pervasive developmental disorder 30.9 SLC6A4 PRODH NRXN1 HTR2A DRD2 DISC1
34 narcolepsy 30.9 SLC6A4 SLC18A2 HTR2A DRD2 COMT BDNF
35 borderline personality disorder 30.8 SLC6A4 PRL HTR2A DRD2 COMT BDNF
36 body dysmorphic disorder 30.8 SLC6A4 SLC1A1 HTR2A
37 conduct disorder 30.8 SLC6A4 DRD4 DRD2 COMT
38 schizotypal personality disorder 30.8 RGS4 PRODH NRG1 HTR2A DTNBP1 DISC1
39 dementia, lewy body 30.8 SLC18A2 MAOB COMT BDNF
40 mental depression 30.8 SLC6A4 PRODH HTR2A DRD4 DRD2 DISC1
41 bipolar i disorder 30.8 SLC6A4 NRG1 HTR2A DTNBP1 DRD2 DAO
42 migraine with or without aura 1 30.7 SLC6A4 PRL MAOB HTR2A DRD4 DRD3
43 adjustment disorder 30.7 SLC6A4 HTR2A BDNF
44 drug dependence 30.7 SLC6A4 DRD3 DRD2 BDNF
45 galactorrhea 30.7 PRL DRD2
46 anxiety 30.7 SLC6A4 SLC1A1 PRODH PRL MAOB HTR2A
47 somatization disorder 30.7 SLC6A4 COMT
48 antisocial personality disorder 30.7 SLC6A4 PRL MAOB HTR2A DRD4 DRD2
49 endogenous depression 30.7 SLC6A4 PRL HTR2A DRD2 COMT BDNF
50 sleep disorder 30.7 SLC6A4 SLC18A2 PRODH PRL HTR2A COMT

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder
Sources

Symptoms & Phenotypes for Psychotic Disorder

About this section

UMLS symptoms related to Psychotic Disorder:


photophobia; lethargy; restlessness; personality changes; agitation; pseudobulbar behavioral symptoms; sleep disturbances; mental and behavioral signs and symptoms; forgetful; decrease in appetite; symptoms; nervousness; feeling jittery; alexithymia; increased libido; numbness; psychiatric symptom; hallucinations, auditory; hallucinations, visual; numbness localized; feeling detached; feeling strange; feeling weightless; floating feeling; dejection emotional; depressed reaction; hallucinations, sensory; restless sleep; difficulty sleeping; excitability; depression aggravated; agitation mental; numb mouth; opiate withdrawal symptoms; clouded consciousness; trembling inside; sluggishness; catatonic reaction

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.7 COMT
2 Decreased viability GR00249-S 9.7 COMT DTNBP1 MAOB PRODH SLC6A4
3 Decreased viability GR00381-A-1 9.7 PRODH SLC6A4
4 Decreased viability GR00381-A-3 9.7 SLC6A4
5 Decreased viability GR00386-A-1 9.7 COMT DAOA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.58 DRD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.58 PRODH
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.58 DRD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.58 PRODH
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.58 DRD3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.58 DRD4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.58 PRODH
13 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.58 PRODH
14 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.58 PRODH
15 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.58 DRD3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.58 DRD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.58 DRD3 DRD4 PRODH
18 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.58 PRODH
19 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.58 PRODH
20 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.58 PRODH
21 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.58 PRODH

MGI Mouse Phenotypes related to Psychotic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 BDNF COMT DAO DISC1 DRD2 DRD3
2 homeostasis/metabolism MP:0005376 10.06 BDNF COMT DAO DISC1 DRD2 DRD3
3 nervous system MP:0003631 9.89 BDNF COMT DAO DISC1 DRD2 DRD3
4 digestive/alimentary MP:0005381 9.8 BDNF DRD2 DRD3 HTR2A NRXN1 SLC18A2
5 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC18A2 SYN2
Sources

Drugs & Therapeutics for Psychotic Disorder

About this section

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 466)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
6
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
7
Fluphenazine Approved Phase 4 69-23-8 3372
8
Pimozide Approved Phase 4 2062-78-4 16362
9
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
10
Thioridazine Approved, Withdrawn Phase 4 50-52-2 5452
11
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
12
Donepezil Approved Phase 4 120014-06-4 3152
13
Amitriptyline Approved Phase 4 50-48-6 2160
14
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
15
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
16
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
17
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
18
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
19
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
20
Sertindole Approved, Investigational, Withdrawn Phase 4 106516-24-9 60149
21
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
22
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
23
Cinnarizine Approved, Investigational Phase 4 298-57-7 1547484 2761
24
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
25 Perazine Approved, Investigational Phase 4 84-97-9
26
Benperidol Approved, Investigational Phase 4 2062-84-2
27
bromperidol Approved, Investigational Phase 4 10457-90-6 2448
28
Cycloserine Approved Phase 4 68-41-7 401 6234
29
Pravastatin Approved Phase 4 81093-37-0 54687
30
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
31
Zinc Approved, Investigational Phase 4 7440-66-6 32051
32
Pramlintide Approved, Investigational Phase 4 151126-32-8
33
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
34
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
35
Allopurinol Approved Phase 4 315-30-0 2094
36
Iron Approved Phase 4 7439-89-6 23925 29936
37
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
38
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
39
Ferrous succinate Approved Phase 4 10030-90-7
40
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 5324346 3404
41
Sodium citrate Approved, Investigational Phase 4 68-04-2
42
Cyproheptadine Approved Phase 4 129-03-3 2913
43
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
44
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
46
Cyclizine Approved Phase 4 82-92-8 6726
47
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
48
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
49
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
50
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386

Interventional clinical trials:

(show top 50) (show all 2100)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine Unknown status NCT02286206 Phase 4 Clozapine
2 A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications Unknown status NCT02213887 Phase 4 Pantoprazole;Pantoprazole
3 Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
4 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
5 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
6 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years Unknown status NCT03883204 Phase 4 Aripiprazole;Risperidone
7 An Open-label Switch Study to Asenapine in the Early Stage of Psychosis Unknown status NCT01968161 Phase 4 Asenapine
8 A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
9 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
10 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
11 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
12 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
13 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Unknown status NCT03495024 Phase 4 Varenicline
14 Comparison of Paracetamol and Dexketoprofen Trometamol on Headache Treatment After Electroconvulsive Treatment Unknown status NCT03830398 Phase 4 Paracetamol;Deksketoprofen trometamol;Placebo
15 Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic REM Sleep Behavior Disorder: a Pilot Study Unknown status NCT02836743 Phase 4 Circadin;Placebo
16 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
17 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
18 Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine Completed NCT00224302 Phase 4 Duloxetine
19 Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics Completed NCT00001656 Phase 4 Olanzapine;Clozapine
20 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
21 Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting. Completed NCT00932529 Phase 4 Olanzapine;Quetiapine;Risperidone;Ziprasidone
22 Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT) Completed NCT00806234 Phase 4 Aripiprazole or Perphenazine;Metformin;Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
23 Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence Completed NCT00215579 Phase 4 Depot Risperidone Microsphere (Consta)
24 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
25 A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder. Completed NCT00521365 Phase 4 Quetiapine 600mg
26 Brain Imaging and Mental Disorders of Aging Intervention Completed NCT00267163 Phase 4 donepezil;Placebo
27 Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana Completed NCT02593734 Phase 4 olanzapine;risperidone;amitryptaline;fluoxetine
28 Sustaining Remission of Psychotic Depression Completed NCT01427608 Phase 4 Sertraline + Olanzapine;Sertraline + Placebo
29 Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia Completed NCT00859872 Phase 4 risperidone oral solution;haloperidol
30 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
31 Prevention of NMDA Antagonist-induced Psychosis and Memory Impairment in Children Completed NCT00205712 Phase 4 Ketamine;Dexmedetomidine
32 Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis Completed NCT00204061 Phase 4 Amisulpride
33 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
34 Pimozide Augmentation of Clozapine in Schizophrenia Completed NCT00158223 Phase 4 Pimozide;Placebo
35 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
36 Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients Completed NCT01119638 Phase 4 Escitalopram;Risperidone
37 Antipsychotic Discontinuation in Alzheimer's Disease Completed NCT00417482 Phase 4 risperidone
38 Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial Completed NCT00396643 Phase 4 Omega 3 fatty acids
39 Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study Completed NCT00272597 Phase 4 Risperidone
40 Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR) Completed NCT00216632 Phase 4 risperidone
41 The Cognitive Effects of Risperidone and Olanzapine Completed NCT00108368 Phase 4 Risperidone;Olanzapine
42 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
43 Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up Completed NCT02526030 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
44 A Multiple-Center, Randomized, Double-Blind Study of Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis Completed NCT01822730 Phase 4 paliperidone;Risperidone
45 Preparing Those With Significant and Persistent Mental Illness to Quit Smoking Completed NCT01783912 Phase 4 Nicotine Patch
46 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
47 An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
48 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
49 An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4 aripiprazole
50 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 70 / NDF-RT 51 :


acetophenazine
Acetophenazine maleate
Carbamazepine
Chlorpromazine
Chlorpromazine hydrochloride
Chlorprothixene
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Droperidol
Fazaclo
Fluphenazine
fluphenazine decanoate
Fluphenazine enanthate
Fluphenazine Hydrochloride
Haloperidol
haloperidol decanoate
Haloperidol lactate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Lorazepam
Loxapine
Loxapine hydrochloride
Loxapine Succinate
Mesoridazine
Mesoridazine besylate
Molindone
Molindone Hydrochloride
Mylan brand of clozapine
olanzapine
Perphenazine
Pimozide
Prochlorperazine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
Promazine
Promazine Hydrochloride
quetiapine
Quetiapine fumarate
Thioridazine
Thioridazine Hydrochloride
Thiothixene
Thiothixene hydrochloride
Trifluoperazine
Trifluoperazine hydrochloride
Triflupromazine
Triflupromazine hydrochloride
UDL brand of clozapine
Sources

Genetic Tests for Psychotic Disorder

About this section
Sources

Anatomical Context for Psychotic Disorder

About this section

MalaCards organs/tissues related to Psychotic Disorder:

40
Brain, Cortex, Eye, Prefrontal Cortex, Pituitary, Temporal Lobe, Skin
Sources

Publications for Psychotic Disorder

About this section

Articles related to Psychotic Disorder:

(show top 50) (show all 9316)
# Title Authors PMID Year
1
Machine learning-based ability to classify psychosis and early stages of disease through parenting and attachment-related variables is associated with social cognition. 42
33757595 2021
2
COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine. 42
33703870 2021
3
Offering mental health first aid to a person experiencing psychosis: a Delphi study to redevelop the guidelines published in 2008. 42
33579387 2021
4
Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders. 54 61
19910055 2010
5
Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. 54 61
19524002 2009
6
Discontinued psychiatric drugs in 2008. 61 54
19715445 2009
7
Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders. 61 54
19692242 2009
8
Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. 61 54
19644230 2009
9
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. 54 61
18562404 2009
10
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. 61 54
19200422 2009
11
Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. 61 54
19268543 2009
12
Association of a nonsynonymous variant of DAOA with visuospatial ability in a bipolar family sample. 54 61
18466879 2008
13
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 54 61
18047755 2008
14
Investigation of serum BDNF levels in drug-naive patients with schizophrenia. 61 54
18502013 2008
15
Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. 61 54
18092319 2008
16
The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. 54 61
17555717 2008
17
A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. 61 54
18162312 2008
18
Association analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patients. 61 54
17822780 2007
19
D-amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia. 54 61
17890006 2007
20
Association of distinct allelic haplotypes of DISC1 with psychotic and bipolar spectrum disorders and with underlying cognitive impairments. 54 61
17673452 2007
21
An association study between cathechol-O-methyltransferase gene and mental retardation in the Chinese Han population. 54 61
17442488 2007
22
Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. 61 54
17445278 2007
23
Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. 61 54
17355517 2007
24
Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. 54 61
17403981 2007
25
The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. 61 54
17267179 2007
26
Diagnostic stability over 3 years in a total group of first-episode psychosis patients. 54 61
17523030 2007
27
Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. 54 61
16793187 2006
28
Risk factors for completed suicide in schizophrenia and other chronic psychotic disorders: a case-control study. 54 61
16626940 2006
29
Common alterations in the serotonin transporter in platelets and lymphocytes of psychotic patients. 54 61
16453253 2006
30
Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia. 61 54
16824690 2006
31
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. 61 54
16232322 2005
32
Hyperprolinemia is a risk factor for schizoaffective disorder. 54 61
15494707 2005
33
Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. 54 61
15211634 2004
34
Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. 61 54
14755448 2004
35
Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. 54 61
15539862 2004
36
GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. 61 54
12811640 2003
37
Premorbid functioning in early-onset psychotic disorders. 54 61
12921474 2003
38
[A case report of factitious disorder with hallucinations]. 61 54
14569475 2003
39
The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. 54 61
11910268 2002
40
Tryptophan hydroxylase gene and major psychoses. 54 61
11472792 2001
41
Children and adolescents with psychotic disorder not otherwise specified: a 2- to 8-year follow-up study. 61 54
11458307 2001
42
DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. 54 61
11353451 2001
43
Dopamine D4 receptor (DRD4) gene polymorphism in the first psychotic episode. 61 54
11282178 2001
44
New neurochemical markers for psychosis: a working hypothesis of their operation. 54 61
11059795 2000
45
Clinical predictors of acute response with quetiapine in psychotic mood disorders. 61 54
10817103 2000
46
Clozapine treatment in a population of adults with mental retardation. 61 54
10695641 2000
47
Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. 61 54
10208638 1999
48
Elevated prolactin in pediatric patients on typical and atypical antipsychotics. 61 54
10630453 1999
49
5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation. 54 61
9881863 1998
50
Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. 61 54
9532348 1998